Karyopharm Therapeutics (NASDAQ:KPTI) Shares Cross Below 200 Day Moving Average – Here’s Why

Karyopharm Therapeutics Inc. (NASDAQ:KPTI)’s share price crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $10.37 and traded as low as $3.51. Karyopharm Therapeutics shares last traded at $3.54, with a volume of 149,206 shares trading hands.

Wall Street Analysts Forecast Growth

KPTI has been the topic of a number of recent research reports. Royal Bank of Canada reiterated an “outperform” rating and set a $45.00 price objective on shares of Karyopharm Therapeutics in a research note on Thursday, February 20th. Robert W. Baird reduced their price objective on Karyopharm Therapeutics from $75.00 to $54.00 and set an “outperform” rating for the company in a research note on Monday, March 3rd. Finally, HC Wainwright increased their price target on shares of Karyopharm Therapeutics from $7.00 to $56.00 and gave the stock a “buy” rating in a report on Wednesday, February 26th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $57.50.

Karyopharm Therapeutics Stock Down 5.3 %

The firm has a market capitalization of $29.80 million, a PE ratio of -3.47 and a beta of 0.11. The firm has a 50-day moving average price of $7.92 and a 200 day moving average price of $10.37.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its earnings results on Wednesday, February 19th. The company reported ($3.60) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.90) by $0.30. The firm had revenue of $30.54 million for the quarter, compared to analysts’ expectations of $30.29 million. Equities research analysts expect that Karyopharm Therapeutics Inc. will post -0.71 earnings per share for the current year.

Institutional Trading of Karyopharm Therapeutics

Several hedge funds have recently modified their holdings of KPTI. Velan Capital Investment Management LP purchased a new stake in shares of Karyopharm Therapeutics during the 4th quarter worth approximately $27,000. Focus Partners Wealth purchased a new position in Karyopharm Therapeutics in the 4th quarter valued at about $31,000. TD Waterhouse Canada Inc. purchased a new stake in Karyopharm Therapeutics in the 4th quarter worth approximately $32,000. Two Sigma Advisers LP grew its position in shares of Karyopharm Therapeutics by 145.5% in the fourth quarter. Two Sigma Advisers LP now owns 76,600 shares of the company’s stock valued at $52,000 after purchasing an additional 45,400 shares during the period. Finally, Opti Capital Management LP purchased a new stake in Karyopharm Therapeutics in the 4th quarter valued at about $85,000. 66.44% of the stock is owned by institutional investors and hedge funds.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).